Diabetes and bone

Hygum, Katrine; Starup-Linde, Jakob; Langdahl, Bente

doi:10.1016/j.afos.2019.05.001

Cited by 63 publications

(44 citation statements)

References 144 publications

(185 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It can be associated with a variety of complications, which can be categorized as macrovascular disease, such as coronary heart disease and cerebral infarction, and microvascular disease, such as diabetic nephropathy, diabetic retinopathy, and diabetic peripheral neuropathy, but it also affects bone health. 1 Diabetic osteoporosis (OP), first identified by Albright et al 2 in 1947, is a form of secondary OP that leads to severe chronic pain and joint dysfunction, and even fracture, and is thus associated with a high prevalence of disability. In recent years, increasing attention has been paid to the deleterious effects of diabetes on bone.…”

Section: Introductionmentioning

confidence: 99%

Effects of Glycated Hemoglobin Level on Bone Metabolism Biomarkers in Patients with Type 2 Diabetes Mellitus

Zhao

Zheng

et al. 2020

DMSO

View full text Add to dashboard Cite

We aimed to determine the relationship between the levels of glycated hemoglobin (HbA1c) and biomarkers of bone metabolism in patients with type 2 diabetes mellitus (T2DM), and whether HbA1c independently influences any of these biomarkers. Patients and Methods: A cohort study of 240 patients with T2DM was performed. Serum was obtained and used to measure HbA1c, total cholesterol (TC), triglycerides, high-density lipoprotein-cholesterol, low-density lipoprotein-cholesterol (LDL-C), very-low-density lipoprotein-cholesterol, apolipoprotein A1 (ApoA1), apolipoprotein B (ApoB), total protein, albumin, blood urea nitrogen (BUN), creatinine, serum 25-hydroxyvitamin D (25OHD), osteocalcin (OC), β-C-terminal cross-linked telopeptide of type I collagen (β-CTX), procollagen type 1 N-terminal propeptide (P1NP), or parathyroid hormone (PTH) concentrations. The participants were divided into three study groups according to HbA1c level: <7%, 7-9% and ≥9%. Chi-square testing and one-way analysis of variance were used to compare groups. The relationships between HbA1c and bone metabolism biomarker values were analyzed using linear correlation analysis and multiple linear regression analysis. Results: Age, duration of T2DM, and the concentrations of TC, LDL-C, apolipoprotein B, albumin, and BUN showed significant difference among the <7%, 7-9% and ≥9% HbA1c groups. Of the bone metabolism biomarkers, there were significant differences in serum 25hydroxyvitamin D (25OHD) and osteocalcin (OC) among the groups. The correlation coefficients (r) for the relationships of HbA1c with 25OHD and OC were −0.200 and −0.183, respectively (P <0.05). Regardless of adjustment for none, some, or all of the confounding factors (age, sex, and duration of T2DM), the 25OHD and OC concentrations were significantly lower in the HbA1c ≥9% group than in the HbA1c <7% group. HbA1c showed no relationship with β-CTX, PINP, or PTH. Conclusion: T2DM patients with poorer glycemic control had lower concentrations of serum 25OHD and OC, suggesting that HbA1c is an independent risk factor for low 25OHD and OC.

show abstract

Section: Introductionmentioning

confidence: 99%

Effects of Glycated Hemoglobin Level on Bone Metabolism Biomarkers in Patients with Type 2 Diabetes Mellitus

Zhao

Zheng

et al. 2020

DMSO

View full text Add to dashboard Cite

show abstract

“…Marin et al and Hygum et al showed that CH causes violation of coordinated action of signaling molecules and regulators of reparative osteogenesis, which leads to decreasing of osteoblast functioning, increasing of adipose tissue amount in regenerates, and significant inhibition of consolidation process [18,19]. Our analysis of osteoreparation stages revealed delay in elimination of the first phase of inflammation in animals with CH.…”

Section: Discussionmentioning

confidence: 53%

Morphological Characteristics and Correction of Long Tubular Bone Regeneration under Chronic Hyperglycemia Influence

Dudchenko

Maksymova

Pikaliuk

et al. 2020

Analytical Cellular Pathology

View full text Add to dashboard Cite

Introduction. Unsatisfactory consequences of bone regeneration disorders in diabetes mellitus (DM) patients, their high prevalence, complication number, and difficulties in treatment require further study and deeper understanding of reparative osteogenesis mechanisms under chronic hyperglycemia and finding new effective and affordable approaches to their treatment. Therefore, the aim of our work was to study the histological, ultramicroscopic, and histomorphometric features of reparative osteogenesis in rats with chronic hyperglycemia (CH), as well as to investigate the possibility of platelet-rich plasma (PRP) use in a fracture area in order to correct the negative effects of CH on reparative osteogenesis processes. Study Object and Methods. The studies were performed on 70 white laboratory rats, mature males, which were divided into the following groups: control group, animals with posttraumatic tibial defect under conditions of CH exposure, rats with experimental CH that were administered with PRP into the bone defect, and animals for the assessment of glucose homeostasis and confirmation of simulated CH. Light microscopy was performed using an Olympus BH-2 microscope (Japan). Ultramicroscopic examination was performed using REM-102 scanning electron microscope. The statistical analysis was performed using SPSS-17 software package. Results. The formation of new bone tissue in animals with CH did not occur after two weeks. Only on the 30th day of reparative osteogenesis the newly formed woven bone tissue was 61.54% of the total regenerated area. It was less than the reference value by 22.89% (P<0.001). On the 14th day of reparative osteogenesis, the regenerated area in a group of animals with CH and PRP injection consisted of connective tissue by 68.94% (4.94% less than in animals with CH (P<0.001)) and woven bone tissue by 31.06%, (13.51% less than in the control group (P<0.001)). On the 30th day, the area of woven bone tissue in a regenerate of this group was less than that of the control group by 12.41% (P<0.001). Conclusion. Thus, chronic hyperglycemia contributes to inflammation delay within the bone defect site, which makes the process of reparative osteogenesis more prolonged. The results of chronic hyperglycemia effect on bone regeneration are also impairment of osteogenic cell proliferation and shift of their differentiation towards the fibrocartilage regenerate formation. The PRP corrects the negative impact of chronic hyperglycemia on reparative osteogenesis, promoting more rapid inflammatory infiltrate removal from the bone defect site and osteogenic beam formation and remodeling of woven bone into lamellar membranous bone tissue.

show abstract

“…A GIP infusion decreased the levels of CTX but not P1NP in patients with T1D 32. The evidence of the incretin response in T1D is conflicting, but both GLP-1 and −2 have been suggested to impact bone turnover 39. The diurnal study showed lower levels of GLP-2 in patients with T1D compared with T2D, and levels of GIP also tended to being lower in patients with T1D28 compared with T2D.…”

Section: Bone Turnover In Type 1 Diabetesmentioning

confidence: 96%

Type 1 Diabetes and Bone Fragility: Links and Risks

Starup-Linde

Hygum

Harsløf

et al. 2019

DMSO

Self Cite

View full text Add to dashboard Cite

Type 1 diabetes (T1D) is associated with an increased fracture risk, which is present at young and old age. Reductions in bone mineral density do not explain the increased fracture risk. Novel scanning modalities suggest that structural deficits may contribute to the increased fracture risk. Furthermore, T1D may due to insulinopenia be a state of low bone turnover. However, diabetes complications and comorbidities may influence fracture risk. Patients with T1D are fearful of falls. The diabetes related complications, hypoglycemic events, and antihypertensive treatment may all lead to falls. Thus, the increased fracture risk in T1D seems to be multifactorial, and earlier intervention with antiosteoporotic medication and focus on fall prevention is needed. This systematic review addresses the epidemiology of fractures and osteoporosis in patients with T1D and the factors that influence fracture risk.

show abstract

Diabetes and bone

Cited by 63 publications

References 144 publications

<p>Effects of Glycated Hemoglobin Level on Bone Metabolism Biomarkers in Patients with Type 2 Diabetes Mellitus</p>

<p>Effects of Glycated Hemoglobin Level on Bone Metabolism Biomarkers in Patients with Type 2 Diabetes Mellitus</p>

Morphological Characteristics and Correction of Long Tubular Bone Regeneration under Chronic Hyperglycemia Influence

<p>Type 1 Diabetes and Bone Fragility: Links and Risks</p>

Contact Info

Product

Resources

About